Embecta Corp. EMBC R2K
Healthcare · Medical Instruments & Supplies · United States
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
READ MORE ›$3.38
-66.57% 1Y
Market & Price
Market Cap
$200.53M
Current Price
$3.38
High / Low (52W)
$14.85 / $2.89
Beta
1.05
Valuation
Stock P/E
1.79
Industry PE
23.65
Forward P/E
1.94
PEG Ratio
-
Book Value
$-10.55
Price to Book
-0.32
P/S
0.19
EV/EBITDA
4.18
Dividend Yield
13.61%
Profitability & Returns
ROCE
29.37%
ROE
-
ROA
16.84%
Profit Margin
10.73%
Op Margin
19.34%
EPS (Latest Qtr)
$-0.07
EPS (TTM)
$1.89
Balance Sheet & Liquidity
Debt/Equity
-
Quick Ratio
1.34
Current Ratio
2.46
Debt
$1.37B
Total Assets
$1.09B
Current Assets
$631.40M
Working Capital
$369.90M
Ownership
Promoter Holding
1.68%
Chg in Prom Hold
-
FII / Inst Holding
100.47%
Chg in FII Hold
0.13%
Financial Snapshot
Enterprise Value
$1.39B
Total Revenue (TTM)
$1.04B
EBITDA
$332.30M
Free Cash Flow
$195.80M
Operating Cash Flow
$213.50M
Shares Outstanding
59.33M
Gross Margin
61.92%
Payout Ratio
31.75%
Growth (CAGR)
Revenue 5Y
-1.47%
Profit 5Y
-24.72%
Revenue (YoY)
-14.40%
Earnings (YoY)
-
PROS
- Healthy ROCE of 29.4%.
- Attractive dividend yield of 13.61%.
- Generates positive free cash flow.
CONS
- Revenue declined at -1.5% CAGR over 5 years.
- Earnings shrank at -24.7% CAGR over 5 years.
- Trading 77.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 24 suggests oversold conditions.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | EMBC Embecta Corp. R2K | 3.38 | 1.79 | $200.53M | 13.61% | 29.37% | - | -1.47% | -24.72% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Dec 2020 | Mar 2021 | Jun 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 284.20M | 295.00M | 289.30M | 274.50M | 291.10M | 275.70M | 277.10M | 286.10M | 277.30M | 287.20M | 272.50M | - | 259.00M | 295.50M | 264.00M | 261.20M | 221.80M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 94.90M | 98.40M | 105.50M | 99.50M | 94.00M |
| Gross Profit | 191.30M | 196.30M | 202.60M | 203.90M | 191.20M | 202.90M | 188.80M | 189.80M | 189.50M | 185.90M | 185.40M | 190.10M | - | 164.10M | 197.10M | 158.50M | 161.70M | 127.80M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 90.40M | 92.10M | 94.20M | 85.40M | 84.90M |
| Operating Income | 124.10M | 126.40M | 124.30M | 116.60M | 98.90M | 97.10M | 88.80M | 55.60M | 51.30M | 45.50M | 39.20M | 55.90M | - | 73.70M | 105.00M | 64.30M | 76.30M | 42.90M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | 74.20M | 110.60M | 60.40M | 95.90M | 44.90M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 26.70M | 26.60M | 26.10M | 24.10M | 22.60M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | 35.80M | 72.20M | 29.00M | 58.90M | 9.50M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | 12.30M | 26.70M | 2.60M | 14.80M | 13.60M |
| Net Income | 105.30M | 107.90M | 104.70M | 98.80M | 79.60M | 62.40M | 35.20M | 14.00M | 15.20M | 20.10M | 28.90M | 14.70M | - | 23.50M | 45.50M | 26.40M | 44.10M | -4.10M |
| Diluted EPS | - | 1.87 | 1.81 | 1.73 | 1.38 | 1.07 | 0.61 | 0.24 | 0.26 | 0.35 | 0.50 | 0.25 | - | 0.40 | 0.78 | 0.45 | 0.74 | -0.07 |
| R&D Expense | 14.00M | 14.10M | 15.70M | 16.70M | 18.00M | 14.30M | 16.90M | 22.10M | 22.60M | 20.20M | 18.40M | 20.40M | 20.30M | 8.00M | 4.40M | - | 4.60M | 5.40M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|
| Revenue | 1.09B | - | 1.13B | 1.12B | 1.12B | 1.08B |
| Cost of Revenue | - | - | 354.60M | 370.90M | 387.90M | 403.60M |
| Gross Profit | 762.60M | - | 774.90M | 749.90M | 735.20M | 676.80M |
| Operating Expenses | - | - | 406.40M | 525.90M | 450.20M | 380.40M |
| Operating Income | 486.50M | - | 368.50M | 224.00M | 285.00M | 296.40M |
| EBITDA | - | - | 334.50M | 245.30M | 192.70M | 284.30M |
| Interest Expense | - | - | 46.20M | 107.00M | 112.30M | 107.30M |
| Pretax Income | - | - | 256.60M | 105.70M | 44.20M | 136.30M |
| Tax Provision | - | - | 33.00M | 35.30M | -34.10M | 40.90M |
| Net Income | 427.60M | - | 223.60M | 70.40M | 78.30M | 95.40M |
| Diluted EPS | 7.50 | - | 3.89 | 1.22 | 1.34 | 1.62 |
| R&D Expense | 61.40M | 63.30M | 66.90M | 85.20M | 78.80M | 37.30M |
Compounded Sales Growth
| 5 Years: | -1.47% |
| 1 Year: | -14.40% |
Compounded Profit Growth
| 5 Years: | -24.72% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -66.57% |
| 6 Months: | -74.34% |
| 3 Months: | -66.96% |
| 1 Month: | -61.08% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | 1.09B | 1.21B | 1.29B | 1.09B |
| Current Assets | - | - | - | 664.70M | 749.10M | 761.00M | 631.40M |
| Cash & Equivalents | - | - | - | 330.90M | 326.30M | 267.50M | 225.50M |
| Inventory | - | - | - | 122.80M | 152.10M | 171.50M | 178.60M |
| Receivables | - | - | - | 22.20M | 16.70M | 193.00M | 145.60M |
| Total Liabilities | - | - | - | 1.98B | 2.04B | 2.02B | 1.74B |
| Current Liabilities | - | - | - | 301.00M | 353.50M | 374.00M | 261.50M |
| Long Term Debt | - | - | - | 1.60B | 1.59B | 1.57B | 1.39B |
| Total Debt | - | - | - | 1.64B | 1.64B | 1.61B | 1.43B |
| Total Equity | 577.10M | 572.20M | - | -891.40M | -821.70M | -738.90M | -651.20M |
| Shares Outstanding | - | - | - | 57.06M | 57.33M | 57.71M | 58.50M |
Cash Flows (Annual)
Figures in USD.
| Metric | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 498.50M | - | 412.20M | 67.70M | 35.70M | 191.70M |
| Investing Cash Flow | -41.90M | - | -24.00M | -26.50M | -15.80M | -9.30M |
| Financing Cash Flow | -456.60M | - | -48.00M | -48.70M | -73.40M | -226.70M |
| Capital Expenditure | -41.90M | - | -24.00M | -26.50M | -15.80M | -9.30M |
| Free Cash Flow | 456.60M | - | 388.20M | 41.20M | 19.90M | 182.40M |
| Net Change in Cash | - | - | 340.20M | -7.50M | -53.50M | -44.30M |
Ratios (Annual)
Figures in %.
| Metric | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | 70.3% | - | 68.6% | 66.9% | 65.5% | 62.6% |
| Operating Margin % | 44.8% | - | 32.6% | 20.0% | 25.4% | 27.4% |
| Net Margin % | 39.4% | - | 19.8% | 6.3% | 7.0% | 8.8% |
| ROE % | 74.7% | - | -25.1% | -8.6% | -10.6% | -14.6% |
| ROCE % | - | - | 46.9% | 26.0% | 31.3% | 35.7% |
Shareholding Pattern
Insiders
1.68%
Institutions
100.47%
Public Float
102.20%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 15.45% | 9.17M | $30.99M |
| 2 | Yacktman Asset Management Lp | 6.19% | 3.67M | $12.41M |
| 3 | River Road Asset Management, LLC | 5.81% | 3.45M | $11.66M |
| 4 | American Century Companies Inc | 5.80% | 3.44M | $11.63M |
| 5 | Vanguard Capital Management LLC | 4.32% | 2.56M | $8.67M |
| 6 | State Street Corporation | 4.29% | 2.55M | $8.61M |
| 7 | Deerfield Management Company, L.P | 4.27% | 2.53M | $8.57M |
| 8 | Jefferies Financial Group Inc. | 3.97% | 2.36M | $7.96M |
| 9 | Sio Capital Management, LLC | 3.11% | 1.85M | $6.25M |
| 10 | Millennium Management Llc | 2.69% | 1.59M | $5.39M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for EMBC
No recent headlines available.